Developer docs
API playgroundTry for free, no card

Search company profiles

Redx Pharma

Full company profile

uuid00046a7

Namestring
Redx Pharma
Legal namestring
Redx Pharma Ltd
Websiteurl
redxpharma.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Redx Pharma is a clinical-stage British biopharmaceutical company developing small-molecule targeted therapies for oncology and fibrotic diseases. Headquartered in Macclesfield, United Kingdom, with 51-100 employees and incorporated as Redx Pharma Ltd, the company is advancing a pipeline of precision medicines built around proprietary chemistry designed to deliver greater specificity and safety than existing therapeutic options. Its lead asset, RXC008 for fibrostenotic Crohn's disease, received FDA Fast Track Designation in March 2026 and is slated to enter Phase 2 trials later in the same year, supported by a research footprint that has historically spanned gastrointestinal, pulmonary fibrosis, and oncology indications.

The company's underlying technology is a medicinal-chemistry-led targeted medicine platform that has produced multiple internally-developed drug candidates, including the KRAS inhibitor program that was licensed and acquired by Jazz Pharmaceuticals in March 2025 to expand the acquirer's oncology pipeline. Redx Pharma's revenue model is asset-centric rather than product-centric: as a clinical-stage originator, it generates income primarily through one-time licensing transactions, milestone payments, and asset sales to larger pharmaceutical partners that possess the resources to fund late-stage clinical development and global commercialization, rather than through direct product sales. Its GTM motion is therefore partner-led, anchored on demonstrating clinical and regulatory milestones that validate its candidates for out-licensing or sale.

Customers of the company are other pharmaceutical firms (Jazz Pharmaceuticals being the named enterprise counterparty) rather than end patients or providers, with therapeutic indications and disease populations serving as downstream markets served through partners. Capital sources have historically included institutional equity investors — most notably a £35 million (~$43 million) placement in May 2022 — alongside grant funding (CARB-X), regional and EU growth capital, and historical LSE listing under ticker REDX.

Short descriptiontext

Redx Pharma is a UK-based clinical-stage biopharmaceutical company developing small-molecule targeted therapies for oncology and fibrotic diseases, partnering with larger pharmaceutical firms to advance its pipeline, with lead candidate RXC008 in Crohn's disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMacclesfield, United Kingdom
HQ citystring
Macclesfield
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
targeted medicine development, clinical-stage biopharmaceutical, precision oncology therapeutics, fibrotic disease treatments, drug discovery pipeline
Industry2 codes
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Asset Sales
TypeLicensing Royalties
Description

Redx Pharma generates revenue through licensing agreements and asset sales to larger pharmaceutical companies. The company sold its KRAS inhibitor program to Jazz Pharmaceuticals and maintains a pipeline of targeted therapies in clinical development.

thepharmaletter.com
2Drug Development and Commercialization
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, Redx Pharma develops proprietary drug candidates through clinical trials with the aim of commercializing them upon regulatory approval.

in.investing.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Redx Pharma is a clinical-stage biopharmaceutical company developing targeted precision medicines for oncology and fibrotic diseases. Its pipeline includes RXC008 for fibrostenotic Crohn's disease (FDA Fast Track Designation) and a KRAS inhibitor program for oncology, which was licensed to Jazz Pharmaceuticals. The company focuses on discovering and developing proprietary drug candidates designed to be more specific and safer than existing therapeutic options.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • FDA Fast Track Designation granted for RXC008 in fibrostenotic Crohn's disease
+1 more record
Product overview1 text field

Redx Pharma is a British targeted medicine company focused on developing precision drugs for oncology and fibrotic diseases. The company's pipeline includes RXC008 for fibrostenotic Crohn's disease and the KRAS inhibitor program for oncology applications.

Product and service2 records
1RXC008
CategoryTargeted Therapeutics
Description

A drug candidate being developed as a potential treatment for fibrostenotic Crohn's disease, designed to be more specific and safer than existing therapeutic options. Received FDA Fast Track Designation with planned Phase 2 trials.

2KRAS Inhibitor Program
CategoryOncology Therapeutics
Description

A targeted oncology drug development program for KRAS-mutated cancers. The program was acquired by Jazz Pharmaceuticals to expand their oncology pipeline and diversify their portfolio.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-03-20
Description

Jazz Pharmaceuticals acquired the KRAS inhibitor program from Redx Pharma as part of their strategy to expand their oncology pipeline and diversify their portfolio. This acquisition represents a significant licensing deal where Redx Pharma transferred rights to its KRAS inhibitor program to Jazz Pharmaceuticals.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Morphic Holding
TypeDirect peer
Description

Clinical-stage biotech developing oral integrin therapies for serious chronic diseases including inflammatory bowel disease. Closely comparable to Redx as a targeted small-molecule company with a GI-focused pipeline addressing fibrostenotic disease.

TypeDirect peer
Description

Clinical-stage precision oncology company developing targeted inhibitors including RAS(ON) inhibitors. Directly comparable to Redx as a precision-medicine oncology developer; the KRAS program was a key shared therapeutic area.

TypeDirect peer
Description

Precision-medicine oncology company developing targeted therapies including KRAS G12C inhibitors. Comparable in approach and disease focus to Redx's pre-divestiture KRAS program.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics for fibrotic diseases, including in lung and GI indications. Directly comparable to Redx as a precision fibrosis drug developer targeting high-unmet-need fibrotic indications.

TypeDirect peer
Description

Targeted oncology company best known for KRAS G12C inhibitors; acquired by Bristol-Myers Squibb. Directly comparable therapeutic-area overlap with Redx's divested KRAS inhibitor program.

TypeBroad incumbent
Description

Global specialty pharmaceutical company focused on neuroscience and oncology. Relevant as both a buyer (licensor of Redx's KRAS program) and a broader incumbent that validates the precision-oncology space Redx operates in.

7Hutchmed (Chi-Med)
TypeRegional player
Description

UK-listed, Asia-rooted precision oncology and immunology drug developer. Comparable as a clinical-stage targeted-medicine company with a similar listing profile and indication mix.

TypeBroad incumbent
Description

Biopharmaceutical company developing therapeutics for fibrotic diseases and anemia, with significant pulmonary fibrosis programs. Comparable as a larger fibrosis-focused peer operating in Redx's adjacent indications.

TypeEmerging player
Description

Clinical-stage precision oncology company developing synthetic-lethal targeted therapies including against KRAS-mutant tumors. Comparable as a smaller, discovery-driven oncology peer with shared precision-medicine DNA.

TypeEmerging player
Description

Precision oncology company developing allosteric mutation-targeted therapies. Comparable as a small-cap, discovery-driven targeted-medicine company working in overlapping oncogenic driver space.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Redx Pharma

Clinical-stage Biopharmaceuticalsredxpharma.com

Redx Pharma is a UK-based clinical-stage biopharmaceutical company developing small-molecule targeted therapies for oncology and fibrotic diseases, partnering with larger pharmaceutical firms to advance its pipeline, with lead candidate RXC008 in Crohn's disease.

What Redx Pharma does

Redx Pharma is a clinical-stage British biopharmaceutical company developing small-molecule targeted therapies for oncology and fibrotic diseases. Headquartered in Macclesfield, United Kingdom, with 51-100 employees and incorporated as Redx Pharma Ltd, the company is advancing a pipeline of precision medicines built around proprietary chemistry designed to deliver greater specificity and safety than existing therapeutic options. Its lead asset, RXC008 for fibrostenotic Crohn's disease, received FDA Fast Track Designation in March 2026 and is slated to enter Phase 2 trials later in the same year, supported by a research footprint that has historically spanned gastrointestinal, pulmonary fibrosis, and oncology indications.

The company's underlying technology is a medicinal-chemistry-led targeted medicine platform that has produced multiple internally-developed drug candidates, including the KRAS inhibitor program that was licensed and acquired by Jazz Pharmaceuticals in March 2025 to expand the acquirer's oncology pipeline. Redx Pharma's revenue model is asset-centric rather than product-centric: as a clinical-stage originator, it generates income primarily through one-time licensing transactions, milestone payments, and asset sales to larger pharmaceutical partners that possess the resources to fund late-stage clinical development and global commercialization, rather than through direct product sales. Its GTM motion is therefore partner-led, anchored on demonstrating clinical and regulatory milestones that validate its candidates for out-licensing or sale.

Customers of the company are other pharmaceutical firms (Jazz Pharmaceuticals being the named enterprise counterparty) rather than end patients or providers, with therapeutic indications and disease populations serving as downstream markets served through partners. Capital sources have historically included institutional equity investors — most notably a £35 million (~$43 million) placement in May 2022 — alongside grant funding (CARB-X), regional and EU growth capital, and historical LSE listing under ticker REDX.

Redx Pharma firmographics

Firmographics
Name
Redx Pharma
Legal name
Redx Pharma Ltd
Website
https://redxpharma.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Redx Pharma is a UK-based clinical-stage biopharmaceutical company developing small-molecule targeted therapies for oncology and fibrotic diseases, partnering with larger pharmaceutical firms to advance its pipeline, with lead candidate RXC008 in Crohn's disease.
Ownership category
akta.pro rank

Redx Pharma industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Targeted medicine development
  • Clinical-stage biopharmaceutical
  • Precision oncology therapeutics
  • Fibrotic disease treatments
  • Drug discovery pipeline

Where Redx Pharma is headquartered

Location

Headquarters

HQ city
Macclesfield
HQ country
United Kingdom
HQ region
Europe

Markets served

Redx Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing and Asset Sales: Redx Pharma generates revenue through licensing agreements and asset sales to larger pharmaceutical companies. The company sold its KRAS inhibitor program to Jazz Pharmaceuticals and maintains a pipeline of targeted therapies in clinical development.
  2. Drug Development and Commercialization: As a clinical-stage biopharmaceutical company, Redx Pharma develops proprietary drug candidates through clinical trials with the aim of commercializing them upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Redx Pharma product offering

Product offering

Core offering

Redx Pharma is a clinical-stage biopharmaceutical company developing targeted precision medicines for oncology and fibrotic diseases. Its pipeline includes RXC008 for fibrostenotic Crohn's disease (FDA Fast Track Designation) and a KRAS inhibitor program for oncology, which was licensed to Jazz Pharmaceuticals. The company focuses on discovering and developing proprietary drug candidates designed to be more specific and safer than existing therapeutic options.

Product overview

Redx Pharma is a British targeted medicine company focused on developing precision drugs for oncology and fibrotic diseases. The company's pipeline includes RXC008 for fibrostenotic Crohn's disease and the KRAS inhibitor program for oncology applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • RXC008 A drug candidate being developed as a potential treatment for fibrostenotic Crohn's disease, designed to be more specific and safer than existing therapeutic options. Received FDA Fast Track Designation with planned Phase 2 trials.
  • KRAS Inhibitor Program A targeted oncology drug development program for KRAS-mutated cancers. The program was acquired by Jazz Pharmaceuticals to expand their oncology pipeline and diversify their portfolio.

Quantifiable outcome

  • FDA Fast Track Designation granted for RXC008 in fibrostenotic Crohn's disease
  • +1 more outcomes

Companies that use Redx Pharma

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Redx Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Redx Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Jazz PharmaceuticalsmajorOEM/ Whitelabel/ Licensing Partner · 20 March 2025Jazz Pharmaceuticals acquired the KRAS inhibitor program from Redx Pharma as part of their strategy to expand their oncology pipeline and diversify their portfolio. This acquisition represents a significant licensing deal where Redx Pharma transferred rights to its KRAS inhibitor program to Jazz Pharmaceuticals.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Redx Pharma competitors and assessment

Company assessment

Direct peers

  • Morphic Holding: Clinical-stage biotech developing oral integrin therapies for serious chronic diseases including inflammatory bowel disease. Closely comparable to Redx as a targeted small-molecule company with a GI-focused pipeline addressing fibrostenotic disease.
  • Revolution Medicines: Clinical-stage precision oncology company developing targeted inhibitors including RAS(ON) inhibitors. Directly comparable to Redx as a precision-medicine oncology developer; the KRAS program was a key shared therapeutic area.
  • Relay Therapeutics: Precision-medicine oncology company developing targeted therapies including KRAS G12C inhibitors. Comparable in approach and disease focus to Redx's pre-divestiture KRAS program.
  • Pliant Therapeutics: Clinical-stage biotech developing therapeutics for fibrotic diseases, including in lung and GI indications. Directly comparable to Redx as a precision fibrosis drug developer targeting high-unmet-need fibrotic indications.
  • Mirati Therapeutics: Targeted oncology company best known for KRAS G12C inhibitors; acquired by Bristol-Myers Squibb. Directly comparable therapeutic-area overlap with Redx's divested KRAS inhibitor program.

Broad incumbents

  • Jazz Pharmaceuticals: Global specialty pharmaceutical company focused on neuroscience and oncology. Relevant as both a buyer (licensor of Redx's KRAS program) and a broader incumbent that validates the precision-oncology space Redx operates in.
  • FibroGen: Biopharmaceutical company developing therapeutics for fibrotic diseases and anemia, with significant pulmonary fibrosis programs. Comparable as a larger fibrosis-focused peer operating in Redx's adjacent indications.

Regional players

  • Hutchmed (Chi-Med): UK-listed, Asia-rooted precision oncology and immunology drug developer. Comparable as a clinical-stage targeted-medicine company with a similar listing profile and indication mix.

Emerging players

  • Repare Therapeutics: Clinical-stage precision oncology company developing synthetic-lethal targeted therapies including against KRAS-mutant tumors. Comparable as a smaller, discovery-driven oncology peer with shared precision-medicine DNA.
  • Black Diamond Therapeutics: Precision oncology company developing allosteric mutation-targeted therapies. Comparable as a small-cap, discovery-driven targeted-medicine company working in overlapping oncogenic driver space.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Redx Pharma social profiles

Digital presence

Redx Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Redx Pharma leadership team

Management profile

Number of profiles

Profiles4 records

Redx Pharma funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Redx Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Redx Pharma

What does Redx Pharma do?

Redx Pharma is a clinical-stage biopharmaceutical company developing targeted precision medicines for oncology and fibrotic diseases. Its pipeline includes RXC008 for fibrostenotic Crohn's disease (FDA Fast Track Designation) and a KRAS inhibitor program for oncology, which was licensed to Jazz Pharmaceuticals. The company focuses on discovering and developing proprietary drug candidates designed to be more specific and safer than existing therapeutic options.

When was Redx Pharma founded?

Redx Pharma was founded in 2010. It employs 11 to 50 people.

Where is Redx Pharma based?

Redx Pharma is headquartered in Macclesfield, United Kingdom, in the Europe region.

How does Redx Pharma make money?

Two revenue lines are on record. Licensing and Asset Sales are the primary driver. The others are drug Development and Commercialization.

Who are Redx Pharma's main competitors?

Direct peers on record are Morphic Holding, Revolution Medicines, Relay Therapeutics, Pliant Therapeutics and Mirati Therapeutics. Broad incumbents are Jazz Pharmaceuticals and FibroGen. Hutchmed (Chi-Med) is listed as a regional player. Emerging players are Repare Therapeutics and Black Diamond Therapeutics.

Does Redx Pharma have an API?

No public API is recorded for Redx Pharma.

What industry is Redx Pharma in?

Redx Pharma's product category is Clinical-stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Insidermedia£3m refurb completes at Mereside Atrium at Alderley Park - investment supporting lettings momentumBruntwood SciTech completed a £3m refurbishment of Mereside Atrium at Alderley Park, creating four new premium office suites and enhanced amenities. The investment is driving lettings momentum, with new arrivals and expansions totaling nearly 19,000 sq ft, including Redx Pharma taking 4,000 sq ft ahead of a merger.The Pharma LetterRedx bolsters gastroenterology expertise with new CMORedx Pharma appointed Dr Mei-Lun Wang as chief medical officer on a permanent basis, strengthening its clinical leadership and gastroenterology expertise. The appointment complements Dr Bernard Coulie's board appointment, both announced on August 27.The UKCheshire pharma testing business Redx completes $36m Series A financingCheshire-headquartered pharma testing business Redx Pharma announced to the stock exchange on August 27 that it has completed a $36 million Series A financing. The company also confirmed a new board composition, with Abingworth managing director Andrew Sinclair joining as investor director and Bernard Coulie as independent director. Abingworth is a transatlantic bioscience investment firm founded in 1973.European BiotechnologyRedx raises $36M to fund Phase 2 Crohn’s disease trialRedx raised $36M in a Series A round, led by Abingworth, to fund its Phase 2 trial of gut-restricted ROCK inhibitor RXC008 for fibrostenotic Crohn's disease. The financing includes a $68M private placement, extending the combined company's cash runway to 2029. Redx aims to report Phase 2 topline data in the second half of 2028.Pulse 2.0Skye Pivots From Obesity To Fibrosis As Fibrx Adds 2027 DDR IND Catalyst Behind Crohn’s Disease ProgramSkye Bioscience is acquiring Redx Pharma in a transaction that will result in the formation of Fibrx Therapeutics, shifting the combined entity's focus from obesity to fibrosis treatments. The new company has secured approximately $125 million in financing and plans to submit an IND for a DDR inhibitor program by 2027, alongside advancing its lead Crohn’s disease asset RXC008 into Phase 2 studies.BioWorldRedx to join Nasdaq via Skye merger; raises $125M privatelyRedx Pharma will join Nasdaq via a merger with Skye Biosciences, listing the combined company as Fibrx Therapeutics. The deal follows Skye's decision not to pursue its obesity treatment nimacimab after it failed to meet expectations. Redx has raised $125M privately.BusinessCloud$125m financing to see Macclesfield’s Redx list on NasdaqRedx Pharma, a Macclesfield-based biotech, agreed a $125m financing deal to list on Nasdaq as Fibrx Therapeutics. The deal includes a $36m Series A led by Abingworth and a $68m private placement, with Sky Bioscience acquiring Redx. The combined company will fund operations through 2029 and key clinical milestones, including RXC008 Phase 2 data expected in H2 2028.Endpoints NewsRedx tries again at reverse merger, with Skye this time, as alternative route gains steamUK fibrosis biotech Redx Pharma is attempting another reverse merger, this time with Skye, following the cancellation of a previous attempt in 2023. The article notes that alternative listing routes are gaining steam for companies seeking public market access.InsidermediaRedx Pharma to be acquired by Nasdaq-listed firm - combined group will be backed by $125m of new financeNasdaq-listed Skye Bioscience has entered into a definitive agreement to acquire Cheshire-based biotechnology firm Redx Pharma, with the combined entity to operate under the name Fibrx Therapeutics. The transaction is supported by approximately $125 million in new financing from a syndicate of investors including Abingworth and British Business Bank. The deal has been approved by both boards and is expected to close in the fourth quarter of 2026.Quiver QuantitativeSkye Bioscience and Redx Pharma Announce Definitive Transaction to Form Fibrx Therapeutics, a Nasdaq-Listed Fibrosis-Focused Company | SKYE Stock NewsSkye Bioscience and Redx Pharma have entered into a definitive agreement to merge, forming Fibrx Therapeutics, which will focus on developing therapies for fibrotic diseases. The transaction is supported by approximately $125 million in financing and expects the combined company to trade on Nasdaq with its lead program, RXC008, entering Phase 2 clinical trials by late 2026.